



(12) Translation of
European patent specification

(11) NO/EP 3567037 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/14 (2006.01)
A61K 31/415 (2006.01)
A61K 31/454 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/497 (2006.01)
A61K 31/506 (2006.01)
C07D 231/14 (2006.01)
C07D 401/06 (2006.01)
C07D 401/10 (2006.01)
C07D 403/10 (2006.01)
C07D 409/14 (2006.01)
C07D 413/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.03.22
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.12.23
(86)	European Application Nr.	19182383.0
(86)	European Filing Date	2015.11.26
(87)	The European Application's Publication Date	2019.11.13
(30)	Priority	2014.11.27, GB, 201421083
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA; MD
(62)	Divided application	EP3224256, 2015.11.26
(73)	Proprietor	Kalvista Pharmaceuticals Limited, Porton Science Park Bybrook Road, Porton DownWiltshire SP4 0BF, Storbritannia
(72)	Inventor	DAVIE, Rebecca Louise, c/o KALVISTA PHARMACEUTICALS LIMITEDPorton Science ParkBybrook RoadPorton Down, Wiltshire, SP4 0BF, Storbritannia EDWARDS, Hannah Joy, c/o KALVISTA PHARMACEUTICALS LIMITEDPorton Science ParkBybrook RoadPorton Down, Wiltshire, SP4 0BF, Storbritannia EVANS, David Michael, c/o KALVISTA PHARMACEUTICALS LIMITEDPorton Science ParkBybrook RoadPorton Down, Wiltshire, SP4 0BF, Storbritannia HODGSON, Simon Teanby, Orchard House, The AvenueAmphill, Bedfordshire, MK45 2NR, Storbritannia

(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS**

(56) References
Cited: WO-A1-2014/108679
WO-A1-2013/111108
WO-A1-2012/017020

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse av Formel (I) eller et farmasøytisk akseptabelt salt eller solvat
derav for anvendelse i en fremgangsmåte ved behandling av en sykdom eller
tilstand hvor plasma kallikrein-aktivitet er implikert, hvor sykdommen eller
5 tilstanden hvor plasma kallikrein-aktivitet er implikert, er valgt fra svekket
synsskarphet, diabetisk retinopati, diabetisk makulært ødem, arvelig angioødem,
diabetes, pankreatitt, hjerneblødning, nefropati, kardiomyopati, nevropati,
inflammatorisk tarmsyndrom, artritt, inflammasjon, septisk sjokk, hypotensjon,
kreft, respiratorisk nødssyndrom hos voksne, disseminert intravaskular
10 koagulering, kardiopulmonær forbigående kirurgi og blødning fra postoperativ
kirurgi, og hvor forbindelsen av Formel (I) er:

